ES2786039T3 - Vector génico - Google Patents
Vector génico Download PDFInfo
- Publication number
- ES2786039T3 ES2786039T3 ES10723305T ES10723305T ES2786039T3 ES 2786039 T3 ES2786039 T3 ES 2786039T3 ES 10723305 T ES10723305 T ES 10723305T ES 10723305 T ES10723305 T ES 10723305T ES 2786039 T3 ES2786039 T3 ES 2786039T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- mir
- galc
- cell
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims abstract description 193
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 213
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 177
- 108091028066 Mir-126 Proteins 0.000 claims abstract description 97
- 108700019146 Transgenes Proteins 0.000 claims abstract description 78
- 238000001415 gene therapy Methods 0.000 claims abstract description 75
- 239000002679 microRNA Substances 0.000 claims abstract description 69
- 230000002132 lysosomal effect Effects 0.000 claims abstract description 13
- 108091070501 miRNA Proteins 0.000 claims abstract description 10
- 108010042681 Galactosylceramidase Proteins 0.000 claims abstract description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 325
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000013603 viral vector Substances 0.000 claims description 19
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 17
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 10
- 208000028226 Krabbe disease Diseases 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- -1 c-Fes Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 3
- 108010082739 NADPH Oxidase 2 Proteins 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 description 239
- 102100028496 Galactocerebrosidase Human genes 0.000 description 220
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 description 219
- 241000699670 Mus sp. Species 0.000 description 128
- 230000000694 effects Effects 0.000 description 115
- 239000005090 green fluorescent protein Substances 0.000 description 99
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 96
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 96
- 238000010361 transduction Methods 0.000 description 65
- 230000026683 transduction Effects 0.000 description 64
- 210000001185 bone marrow Anatomy 0.000 description 58
- 108091062140 Mir-223 Proteins 0.000 description 57
- 210000000130 stem cell Anatomy 0.000 description 46
- 230000001105 regulatory effect Effects 0.000 description 40
- 230000006907 apoptotic process Effects 0.000 description 36
- 230000004069 differentiation Effects 0.000 description 34
- 230000033228 biological regulation Effects 0.000 description 33
- 241001529936 Murinae Species 0.000 description 32
- 238000002054 transplantation Methods 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- 230000001988 toxicity Effects 0.000 description 28
- 231100000419 toxicity Toxicity 0.000 description 28
- 230000003394 haemopoietic effect Effects 0.000 description 26
- 102100022146 Arylsulfatase A Human genes 0.000 description 25
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 25
- 210000001616 monocyte Anatomy 0.000 description 24
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 21
- 238000012288 TUNEL assay Methods 0.000 description 20
- 230000007774 longterm Effects 0.000 description 20
- 210000002540 macrophage Anatomy 0.000 description 20
- 230000002018 overexpression Effects 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 210000004700 fetal blood Anatomy 0.000 description 19
- 210000005259 peripheral blood Anatomy 0.000 description 19
- 239000011886 peripheral blood Substances 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 210000000274 microglia Anatomy 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 102000006601 Thymidine Kinase Human genes 0.000 description 17
- 108020004440 Thymidine kinase Proteins 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 16
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 16
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 230000003021 clonogenic effect Effects 0.000 description 15
- 230000000925 erythroid effect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000008901 benefit Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 231100000331 toxic Toxicity 0.000 description 14
- 230000002588 toxic effect Effects 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 210000003714 granulocyte Anatomy 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000004248 oligodendroglia Anatomy 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000002457 bidirectional effect Effects 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 210000000066 myeloid cell Anatomy 0.000 description 12
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 11
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 101150022753 galc gene Proteins 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 9
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 208000015439 Lysosomal storage disease Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000001190 Q-PCR Methods 0.000 description 8
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 8
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 230000009760 functional impairment Effects 0.000 description 8
- 210000000777 hematopoietic system Anatomy 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000009368 gene silencing by RNA Effects 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010068051 Chimerism Diseases 0.000 description 5
- 101150082542 Gld gene Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108091007420 miR‐142 Proteins 0.000 description 5
- 230000001124 posttranscriptional effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000013042 tunel staining Methods 0.000 description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 238000013394 immunophenotyping Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000003593 megakaryocyte Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 101150053137 AIF1 gene Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 102100036008 CD48 antigen Human genes 0.000 description 3
- 102000003908 Cathepsin D Human genes 0.000 description 3
- 108090000258 Cathepsin D Proteins 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 3
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 3
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 210000002960 bfu-e Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000003013 erythroid precursor cell Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108091023084 miR-126 stem-loop Proteins 0.000 description 3
- 108091065272 miR-126-1 stem-loop Proteins 0.000 description 3
- 108091081187 miR-126-2 stem-loop Proteins 0.000 description 3
- 108091030790 miR-126-3 stem-loop Proteins 0.000 description 3
- 108091092317 miR-126-4 stem-loop Proteins 0.000 description 3
- 108091064378 miR-196b stem-loop Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001400 myeloablative effect Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 101150088952 IGF1 gene Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 2
- 101710183243 Serine/threonine-protein kinase PLK2 Proteins 0.000 description 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000027522 Sydenham chorea Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008436 biogenesis Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 231100001129 embryonic lethality Toxicity 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108091091807 let-7a stem-loop Proteins 0.000 description 2
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 2
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 2
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 2
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001237 metamyelocyte Anatomy 0.000 description 2
- 108091091751 miR-17 stem-loop Proteins 0.000 description 2
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 2
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 101150084229 ATXN1 gene Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 102000004201 Ceramidases Human genes 0.000 description 1
- 108090000751 Ceramidases Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 108010072732 Core Binding Factors Proteins 0.000 description 1
- 102000006990 Core Binding Factors Human genes 0.000 description 1
- 101710186553 Cytochrome b-245 heavy chain Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 210000001783 ELP Anatomy 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 1
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 1
- 101000658608 Homo sapiens Tetraspanin-32 Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 102100037691 Kinesin-like protein KIF20B Human genes 0.000 description 1
- 108050007394 Kinesin-like protein KIF20B Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710081489 Protein argonaute Proteins 0.000 description 1
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102100037614 Sprouty-related, EVH1 domain-containing protein 1 Human genes 0.000 description 1
- 101710112213 Sprouty-related, EVH1 domain-containing protein 1 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- 102100034915 Tetraspanin-32 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091079627 Type III family Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000005233 cap myopathy Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000002791 cfu-m Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 108091000370 double-stranded RNA binding proteins Proteins 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000004670 early embryonic cell Anatomy 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 201000010062 epididymo-orchitis Diseases 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 101150090192 how gene Proteins 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002754 ksl cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007653 larval development Effects 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 108091023663 let-7 stem-loop Proteins 0.000 description 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108091053735 lin-4 stem-loop Proteins 0.000 description 1
- 108091032363 lin-4-1 stem-loop Proteins 0.000 description 1
- 108091028008 lin-4-2 stem-loop Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 108091035155 miR-10a stem-loop Proteins 0.000 description 1
- 108091055434 miR-124a stem-loop Proteins 0.000 description 1
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 description 1
- 108091050112 miR-124a-4 stem-loop Proteins 0.000 description 1
- 108091054623 miR-124a-5 stem-loop Proteins 0.000 description 1
- 108091024680 miR-124a-6 stem-loop Proteins 0.000 description 1
- 108091051410 miR-130 stem-loop Proteins 0.000 description 1
- 108091050366 miR-130-1 stem-loop Proteins 0.000 description 1
- 108091054878 miR-130-2 stem-loop Proteins 0.000 description 1
- 108091074848 miR-19 stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091084454 miR-302a stem-loop Proteins 0.000 description 1
- 108091043953 miR-373 stem-loop Proteins 0.000 description 1
- 108091032902 miR-93 stem-loop Proteins 0.000 description 1
- 108091032454 miR-93a stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000006681 severe congenital neutropenia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006426 vascular sprouting Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17412409P | 2009-04-30 | 2009-04-30 | |
| PCT/IB2010/001166 WO2010125471A2 (en) | 2009-04-30 | 2010-04-30 | Gene vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2786039T3 true ES2786039T3 (es) | 2020-10-08 |
Family
ID=42790671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10723305T Active ES2786039T3 (es) | 2009-04-30 | 2010-04-30 | Vector génico |
Country Status (23)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011011508A (es) | 2009-04-30 | 2012-02-13 | San Raffaele Centro Fond | Vector genico. |
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| WO2012006577A2 (en) * | 2010-07-08 | 2012-01-12 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013152230A1 (en) * | 2012-04-04 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Smooth muscle specific inhibition for anti-restenotic therapy |
| GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| CA2878037C (en) * | 2012-07-11 | 2021-08-31 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
| CA2891347C (en) | 2012-12-06 | 2018-02-27 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| PL2956477T5 (pl) | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| AU2014235794A1 (en) | 2013-03-14 | 2015-10-22 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
| EP3060670B1 (en) | 2013-10-24 | 2019-07-10 | Ospedale San Raffaele S.r.l. | Method |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EP3318630B1 (en) * | 2015-04-22 | 2020-11-04 | iPS Academia Japan, Inc. | Method for sorting tissue cells |
| WO2016201507A1 (en) * | 2015-06-15 | 2016-12-22 | Murdoch Childrens Research Institute | Method of measuring chimerism |
| US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
| RS63548B1 (sr) | 2016-02-01 | 2022-09-30 | Bioverativ Therapeutics Inc | Optimizovani geni faktora viii |
| GB201612214D0 (en) | 2016-07-14 | 2016-08-31 | Univ Oxford Innovation Ltd | Method |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| CA3040303A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| CN106566838B (zh) * | 2016-11-14 | 2019-11-01 | 上海伯豪生物技术有限公司 | 一种基于CRISPR-Cas9技术的miR-126全长基因敲除试剂盒及其应用 |
| WO2018193119A1 (en) * | 2017-04-21 | 2018-10-25 | Ospedale San Raffaele S.R.L. | Gene therapy |
| IT201700086403A1 (it) * | 2017-07-27 | 2019-01-27 | Univ Del Piemonte Orientale | Endothelial-specific promoter sequences and uses thereof |
| KR20250040746A (ko) | 2017-08-09 | 2025-03-24 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| CN111918674A (zh) | 2018-02-01 | 2020-11-10 | 比奥维拉迪维治疗股份有限公司 | 表达因子viii的慢病毒载体的用途 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| SG11202105880TA (en) | 2018-12-06 | 2021-07-29 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor ix |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| CA3161175A1 (en) * | 2019-11-12 | 2021-05-20 | The Regents Of The University Of California | Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous disease |
| BR112022026127A2 (pt) | 2020-06-24 | 2023-01-17 | Bioverativ Therapeutics Inc | Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína |
| AU2021330936A1 (en) | 2020-08-23 | 2023-05-04 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| JP2024534123A (ja) | 2021-08-23 | 2024-09-18 | バイオベラティブ セラピューティクス インコーポレイテッド | バキュロウイルス発現システム |
| TW202323274A (zh) | 2021-08-23 | 2023-06-16 | 美商百歐維拉提夫治療公司 | 優化因子viii基因 |
| CN115725656A (zh) * | 2021-09-01 | 2023-03-03 | 联邦生物科技(珠海横琴)有限公司 | 一种以细胞质rna病毒为载体递送干扰rna的方法 |
| AU2022355088A1 (en) | 2021-09-30 | 2024-05-16 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
| EP4561638A2 (en) * | 2022-07-25 | 2025-06-04 | ModernaTX, Inc. | Engineered polynucleotides for cell selective expression |
| WO2025122739A1 (en) * | 2023-12-05 | 2025-06-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for treating a heart disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6118001A (en) | 1996-08-07 | 2000-09-12 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| NZ532060A (en) * | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20060134784A1 (en) * | 2004-11-30 | 2006-06-22 | Basch Ross S | Methods and compositions for the growth and maintenance of stem cells |
| SI2002003T1 (sl) | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| CA2610702A1 (en) * | 2005-06-03 | 2006-12-07 | Michael Zenon Michael | Targeting cells with altered microrna expression |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| EP2479286B1 (en) | 2006-01-05 | 2013-11-13 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| US20080095750A1 (en) | 2006-05-10 | 2008-04-24 | Pennington Biomedical Research Center, Louisiana State University System | Use of adipose-derived stem cells for treatment of leukodystrophies |
| WO2008073921A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-126 regulated genes and pathways as targets for therapeutic intervention |
| ES2635726T3 (es) | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
| EP2364362B1 (en) | 2008-11-12 | 2015-10-21 | Ospedale San Raffaele S.r.l. | Gene vector for inducing transgene-specific immune tolerance |
| MX2011011508A (es) * | 2009-04-30 | 2012-02-13 | San Raffaele Centro Fond | Vector genico. |
-
2010
- 2010-04-30 MX MX2011011508A patent/MX2011011508A/es active IP Right Grant
- 2010-04-30 PT PT107233058T patent/PT2424571T/pt unknown
- 2010-04-30 EP EP20167404.1A patent/EP3733214A1/en active Pending
- 2010-04-30 JP JP2012507847A patent/JP6144911B2/ja active Active
- 2010-04-30 SI SI201032001T patent/SI2424571T1/sl unknown
- 2010-04-30 PL PL10723305T patent/PL2424571T3/pl unknown
- 2010-04-30 EA EA201171335A patent/EA023938B1/ru not_active IP Right Cessation
- 2010-04-30 HR HRP20200647TT patent/HRP20200647T1/hr unknown
- 2010-04-30 SG SG2011080009A patent/SG175839A1/en unknown
- 2010-04-30 AU AU2010243276A patent/AU2010243276B2/en active Active
- 2010-04-30 LT LTEP10723305.8T patent/LT2424571T/lt unknown
- 2010-04-30 SG SG10201610827RA patent/SG10201610827RA/en unknown
- 2010-04-30 KR KR1020117028569A patent/KR101793615B1/ko active Active
- 2010-04-30 DK DK10723305.8T patent/DK2424571T3/da active
- 2010-04-30 HU HUE10723305A patent/HUE049845T2/hu unknown
- 2010-04-30 CN CN201080030337.7A patent/CN102596255B/zh active Active
- 2010-04-30 ES ES10723305T patent/ES2786039T3/es active Active
- 2010-04-30 US US13/266,381 patent/US10287579B2/en active Active
- 2010-04-30 CA CA2759438A patent/CA2759438C/en active Active
- 2010-04-30 WO PCT/IB2010/001166 patent/WO2010125471A2/en not_active Ceased
- 2010-04-30 BR BRPI1010873A patent/BRPI1010873B1/pt active IP Right Grant
- 2010-04-30 SM SM20200224T patent/SMT202000224T1/it unknown
- 2010-04-30 EP EP10723305.8A patent/EP2424571B1/en active Active
-
2011
- 2011-10-23 IL IL215804A patent/IL215804A/en active IP Right Grant
-
2015
- 2015-09-07 JP JP2015175986A patent/JP6370278B2/ja active Active
-
2017
- 2017-08-31 US US15/693,112 patent/US9951328B2/en active Active
-
2019
- 2019-04-15 US US16/384,571 patent/US11407996B2/en active Active
-
2020
- 2020-05-04 CY CY20201100405T patent/CY1123218T1/el unknown
-
2022
- 2022-06-30 US US17/855,135 patent/US20220333103A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2786039T3 (es) | Vector génico | |
| Wang et al. | Brain endothelial cells maintain lactate homeostasis and control adult hippocampal neurogenesis | |
| Shilo et al. | MicroRNA in cutaneous wound healing: a new paradigm | |
| ES2744186T3 (es) | Composiciones y métodos para tratar las hemoglobinopatías | |
| EP2627766B1 (en) | Methods and compositions for the treatment of insulin-associated medical conditions | |
| WO2010151755A2 (en) | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 | |
| JP2024540972A (ja) | 加齢性白質喪失の若返り治療 | |
| Yang et al. | Mir-184 contributes to brain injury through targeting PPAP2B following ischemic stroke in male rats | |
| US20150203846A1 (en) | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F6 | |
| Schiffelers et al. | siRNA-mediated inhibition of angiogenesis | |
| US20150283164A1 (en) | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 | |
| Lavenniah | Synthetic circular miRNA Sponges as a Novel miRNA Interference Technology | |
| Hsu | Identification and characterization of microRNAs which moderate neutrophil migration and acute inflammation | |
| Guess | Characterization of microRNA Function During Skeletal Myogenesis | |
| Stephanou | Advancing Lentiviral Gene Therapy Vectors for Β-thalassaemia | |
| Tan | Tuning of Neuronal Excitation by a Brain Specific Microrna MIR-128: From Targets to Behavior | |
| Garcia | Study of the murine Stem Cell E3 Ubiquitin ligase Lin41 in Development and Postnatal stages through the characterization of Lin41 Gene Trap and conditional Knockout models |